Capital International Sarl Sells 5,919 Shares of Ascendis Pharma A/S $ASND

Capital International Sarl decreased its position in Ascendis Pharma A/S (NASDAQ:ASND) by 19.2% during the fourth quarter, HoldingsChannel.com reports. The fund owned 24,943 shares of the biotechnology company’s stock after selling 5,919 shares during the quarter. Capital International Sarl’s holdings in Ascendis Pharma A/S were worth $5,319,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in ASND. Cetera Investment Advisers bought a new stake in Ascendis Pharma A/S in the 2nd quarter worth approximately $552,000. Rhumbline Advisers increased its stake in Ascendis Pharma A/S by 4.0% in the 2nd quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company’s stock worth $249,000 after acquiring an additional 55 shares during the last quarter. Daiwa Securities Group Inc. increased its stake in Ascendis Pharma A/S by 66.2% in the 2nd quarter. Daiwa Securities Group Inc. now owns 3,737 shares of the biotechnology company’s stock worth $645,000 after acquiring an additional 1,488 shares during the last quarter. Qube Research & Technologies Ltd increased its stake in Ascendis Pharma A/S by 83.4% in the 2nd quarter. Qube Research & Technologies Ltd now owns 201,044 shares of the biotechnology company’s stock worth $34,700,000 after acquiring an additional 91,412 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new stake in Ascendis Pharma A/S in the 2nd quarter worth approximately $897,000.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Royal Bank Of Canada increased their price target on Ascendis Pharma A/S from $250.00 to $275.00 and gave the company an “outperform” rating in a report on Monday, March 2nd. Barclays increased their price target on Ascendis Pharma A/S from $342.00 to $345.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Bank of America increased their price target on Ascendis Pharma A/S from $262.00 to $292.00 and gave the company a “buy” rating in a report on Thursday, April 16th. Wells Fargo & Company decreased their price target on Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Finally, Jefferies Financial Group assumed coverage on Ascendis Pharma A/S in a report on Monday, March 16th. They set a “buy” rating and a $290.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $295.39.

Ascendis Pharma A/S Stock Performance

Shares of Ascendis Pharma A/S stock opened at $210.45 on Monday. The stock’s fifty day moving average is $233.16 and its two-hundred day moving average is $223.65. The company has a market capitalization of $13.13 billion, a PE ratio of 24.27 and a beta of 0.39. The company has a quick ratio of 0.72, a current ratio of 1.00 and a debt-to-equity ratio of 0.79. Ascendis Pharma A/S has a 52 week low of $160.86 and a 52 week high of $250.74.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.21 by $0.11. The business had revenue of $285.45 million during the quarter, compared to the consensus estimate of $362.47 million. As a group, analysts expect that Ascendis Pharma A/S will post 12.85 earnings per share for the current year.

Insider Buying and Selling at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, Director Jean Jacques Bienaime acquired 400 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were bought at an average price of $237.80 per share, with a total value of $95,120.00. Following the transaction, the director directly owned 400 shares of the company’s stock, valued at $95,120. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, insider Flemming Steen Jensen sold 19,460 shares of the company’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $238.49, for a total value of $4,641,015.40. The SEC filing for this sale provides additional information. Corporate insiders own 40.00% of the company’s stock.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.